

NUMBER OF SHARES AND VOTES IN CINCLUS PHARMA

The number of shares and votes in Cinclus Pharma Holding AB (publ) ("Cinclus Pharma") has changed as a result of the issue and repurchase of 854,430 class C shares in accordance with the Board of Directors' resolution announced on 28 November 2024 and registered with the Swedish Companies Registration Office on 3 December 2024

As of 30 December 2024, the last trading day of the month, the total number of shares in Cinclus Pharma amounts to 47,392,219, of which 46,537,789 are ordinary shares and 854,430 are class C shares. The total number of votes amounts to 46,623,232, of which the ordinary shares correspond to 46,537,789 votes and the class C shares correspond to 85,443 votes. The company's share capital has through the issue increased by approximately SEK 16,588, from approximately SEK 903,451 to approximately SEK 920,039.

Ordinary shares entitle the holder to one vote per share, while class C shares entitle the holder to 1/10 vote. The C-shares will be held by the company to be used in the future for its long-term share-based incentive programs.

For additional information, please contact:

Christer Ahlberg, CEO
Phone: +46 70 675 33 30
e-mail: christer.ahlberg@cincluspharma.com

Charlotte Stjerngren, IR
Phone: +46 70 876 87 87
e-mail: charlotte.stjerngren@cincluspharma.com

This information is information that Cinclus Pharma Holding AB (publ) is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2024-12-30 14:00 CET.

About Cinclus Pharma

Cinclus Pharma Holding AB (publ) is a late-stage clinical pharmaceutical company developing drugs for the treatment of acid-related diseases and disorders of the upper gastrointestinal tract. The company's leading drug candidate is linaprazan glurate, a prodrug of P-CAB linaprazan, which was originally developed by AstraZeneca. Linaprazan glurate has the potential to heal erosions in the esophageal mucosa and relieve symptoms of gastroesophageal reflux disease (GERD) more effectively than current treatments like proton pump inhibitors (PPI). The safety and efficacy of linaprazan and linaprazan glurate have been documented in over 30 phase I and two phase II studies involving more than 3,000 participants. Planning for phase III studies is currently underway, with an expected start in 2025. GERD affects approximately 133 million adults in the US and EU, and there is a significant need for new drugs to treat the most severe cases: around 10 million patients. Linaprazan glurate is developed to meet these needs. For more information, visit www.cincluspharma.com.

Attachments

Number of shares and votes in Cinclus Pharma